Pimasertib
- Generic Name
- Pimasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15FIN3O3
- CAS Number
- 1236699-92-5
- Unique Ingredient Identifier
- 6ON9RK82AL
- Background
Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).
- Associated Conditions
- -
- Associated Therapies
- -
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-07-12
- Target Recruit Count
- 82
- Registration Number
- NCT06208657
- Locations
- 🇦🇺
John Hunter Children's Hospital, Newcastle, New South Wales, Australia
🇦🇺Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia
🇦🇺Queensland Children's Hospital, Brisbane, Queensland, Australia
Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Day One Biopharmaceuticals, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT04985604
- Locations
- 🇺🇸
The Angeles Clinic, Los Angeles, California, United States
🇺🇸Hoag Health, Newport Beach, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast AdenocarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Triple-Negative Breast CarcinomaStage IVA Lung Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Stage IVB Lung Cancer AJCC v8Hematopoietic and Lymphoid Cell NeoplasmMetastatic Melanoma
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT04789668
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 26
- Registration Number
- NCT01985191
- Locations
- 🇳🇱
Investigational Site Number 528002, Utrecht, Netherlands
🇫🇷Investigational Site Number 250001, Villejuif Cedex, France
🇳🇱Investigational Site Number 528003, Rotterdam, Netherlands
Oral Bioavailability and Mass Balance Trial With Pimasertib
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 6
- Registration Number
- NCT01713036
- Locations
- ðŸ‡ðŸ‡º
Research Site, Budapest, Hungary
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 194
- Registration Number
- NCT01693068
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
🇩🇪Research site, München, Germany
🇺🇸Please contact the US Medical Information in, Rockland, Massachusetts, United States
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 26
- Registration Number
- NCT01668017
- Locations
- 🇯🇵
Please contact, Merck Serono Co., Ltd for recruiting locations in, Japan
Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 33
- Registration Number
- NCT01378377
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸For Recruiting Locations in the US contact US Medical Information in, Rockland, Massachusetts, United States
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 16
- Registration Number
- NCT01085331
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-11-19
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 141
- Registration Number
- NCT01016483
- Locations
- 🇺🇸
For Recruiting Locations in the United States, please Contact U.S. Medical Information, Rockland, Massachusetts, United States
🇩🇪For Recruiting Locations outside the United States, Please contact the Merck KGaA Communication Center, Darmstadt, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.